References
- Cacabelos R. Parkinson’s disease: from pathogenesis to pharmacogenomics. Int J Mol Sci. 2017;18(3):551.
- Pirtošek Z, Bajenaru O, Kovács N, et al. Update on the management of Parkinson’s disease for general neurologists. Parkinsons Dis. 2020;2020:9131474.
- Song Z, Zhang J, Xue T, et al. Different catechol-O-methyl transferase inhibitors in Parkinson’s disease: a Bayesian network meta-analysis. Front Neurol. 2021;12:707723.
- Brooks DJ, Sagar H, UK-Irish Entacapone Study Group. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson’s disease: a randomized, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry. 2003;74(8):1071–1079.
- Fénelon G, Giménez-Roldán S, Montastruc JL, et al. Efficacy and tolerability of entacapone in patients with Parkinson’s disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study. J Neural Transm (Vienna). 2003;110:239–251.
- Poewe WH, Deuschl G, Gordin A, et al. Efficacy and safety of entacapone in Parkinson’s disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand. 2002;105:245–255.
- Reichmann H, Boas J, Macmahon D, et al., Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. Acta Neurol Scand. 111(1): 21–28. 2005.
- Rinne UK, Larsen JP, Siden A, et al. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology. 1998;51:1309–1314.
- Baas H, Beiske AG, Ghika J, et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the “wearing off” phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry. 1997;63:421–428.
- Dupont E, Burgunder JM, Findley LJ, et al. Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Tolcapone in Parkinson’s Disease Study Group II (TIPS II). Mov Disord. 1997;12:928–934.
- Rajput AH, Martin W, Saint-Hilaire MH, et al. Tolcapone improves motor function in parkinsonian patients with the ”wearing-off” phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology. 1998;50:54–59.
- Shan DE, Lee SJ, Chao LY, et al. Gait analysis in advanced Parkinson’s disease - effect of levodopa and tolcapone. Can J Neurol Sci. 2001;28:70–75.
- Waters CH, Kurth M, Bailey P, et al. Tolcapone in stable Parkinson’s disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group. Neurology. 1997;49:665–671.
- Artusi CA, Sarro L, Imbalzano G, et al. Safety and efficacy of tolcapone in Parkinson’s disease: systematic review. Eur J Clin Pharmacol. 2021;77:817–829.
- Deane K, Spieker S, Clarke CE. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson’s disease. Cochrane Database Syst Rev. 2004;4:CD00455. .
- Lees AJ, Ferreira J, Rascol O, et al. Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol. 2017;74(2):197–206.
- Takeda A, Takahashi R, Tsuboi Y, et al. Randomized, controlled study of Opicapone in Japanese Parkinson’s patients with motor fluctuations. Mov Disord. 2021;36:415–423.
- Ferreira JJ, Lees A, Rocha JF, et al. Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016;15:154–165.
- Rocha JF, Ebersbach G, Lees A, et al. The added benefit of opicapone when used early in Parkinson’s disease patients with levodopa-induced motor fluctuations: a post-hoc analysis of BIPARK-I and -II. Front Neurol. 2021;12:754016.
- Reichmann H, Lees A, Rocha JF, et al. Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study. Transl Neurodegener. 2020;9:9.
- Müller T. Catechol-O-Methyltransferase inhibitors in Parkinson’s disease. Drugs. 2015;75(2):157–174.
- Jenner P, Rocha J, Ferreira JJ, et al. Redefining the strategy for the use of COMT inhibitors in Parkinson’s disease: the role of opicapone. Expert Rev Neurother. 2021;21(9):1019–1033.